Medpace Continues to Grow in Europe
News Aug 19, 2015
The new office is roughly three times the size of the former facility, allowing for significant growth in Data Management, Bio Statistics, Quality Assurance, Regulatory Affairs, Clinical Operations, and Safety. Together with the recently expanded London office, Medpace continues to invest in additional capacity for our operations globally. The UK offices in London and Stirling, Scotland, now houses close to 130 Medpace employees.
Medpace has focused expansion efforts in Europe over the past few years. The European activities have included adding additional clinical research professionals and expanding facilities in the United Kingdom, Poland, Russia, France, Germany and future significant office expansions planned for 2015/2016 in Leuven (Belgium), Prague (Czech Republic), Madrid (Spain). Medpace offices in Europe offer clinical operational support for a rapidly expanding Global and European market. Medpace established its first European office in the Czech Republic in 2005. Medpace employees in Europe now account for over one third of Medpace global employees.
With 12 European offices serving 30 EU countries, Medpace continues to grow and supply innovative support for studies in oncology, cardio metabolic, infectious disease, CNS, and other growing therapeutic areas. All European offices are fully integrated with Medpace global development services.
New Cell-weighing Technique Helps Predict How Drugs Affect Cancer CellsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE